In vitro SGID of intact and hydrolysed MPI 156
In vitro SGID was conducted with unhydrolysed MPI and H16 as outlined in Walsh et al. (2004) . 157
Briefly, samples were resuspended in distilled water to 2% (w protein equivalent /w) for 30 min 158 at 37°C and the pH was adjusted to 2.0 using 1 N HCl. Hydrolysis with pepsin (E:S 2.5% (w/w)) 159 was carried out under pH regulation (2.0) with HCl (pH stat Titrando 843, Tiamo 1.4 Metrohm, 160
Dublin, Ireland) for 90 min at 37°C. Pepsin was then heat inactivated (90°C, 20 min). An aliquot 161 of the peptic hydrolysate (MPI_pepsin or H16_pepsin) was brought to pH 7.5 using 1 M NaOH 162 and then hydrolysed with CorPP (E:S 1% (w/w)) for 150 min at 37°C, pH 7.5 using a pH stat
DPP-IV inhibition assay 166
The DPP-IV inhibition assay was carried out in triplicate as outlined by Nongonierma and 167
FitzGerald (2013a). The freeze-dried samples were dispersed in HPLC grade water at 168 concentrations ranging from 1.1 × 10 -2 to 2.7 mg mL -1 (final concentration expressed in mg 169 protein equivalent mL -1 ). Diprotin A, a well-known DPP-IV inhibitor, was used as a positive 170 control at final concentrations ranging from 12.5 × 10 -2 and 12.5 µg mL 
DH determination 181
The DH of the hydrolysates (H1-H16) was determined in triplicate (n=3) using the TNBS method 182 as per Le Maux, Nongonierma, Barre, and FitzGerald (2016 Bioinformatics Solutions Inc, Waterloo, Canada). The false discovery rate (FDR), average local 227 confidence (ALC) and MS/MS tolerance were set at 1, 60% and 0.1 Da respectively. In addition, 228 synthetic peptides (Ala-Leu, Phe-Leu, Leu-Leu/Ile-Leu/Leu-Ile/Ile-Ile, Leu-Pro-Leu, Val-Leu, 229
Trp-Gln, Trp-Lys, Trp-Tyr, Tyr-Leu/Tyr-Ile) were used to spike hydrolysate samples, which 230 were subsequently analysed using the same LC-MS/MS conditions in order to confirm the 231 software identification (data not shown). All other amino acid sequences generated by PEAKS 232
Studio software were manually checked in order to (1) verify that the peptide sequence 233 corresponded with the same amino acid sequence in the main milk proteins and (2) control the 234 peptides fragmentation data as ion series continuity and major peaks identified as b or y ions. 235
Previously identified DPP-IV inhibitory peptides within the samples were then determined. In 236 addition, features of known DPP-IV inhibitory peptides reported in the literature, which consist in 237 an hydrophobic amino acid (Trp, Leu, Ile or Phe) at the N-terminus and/or a Pro/Ala at position2, and/or Pro at the C-terminus (Nongonierma & FitzGerald, 2013b , 2014a The molecular mass distribution profiles (Fig. 1 ) of the hydrolysates H1-H15 showed the 252 presence of components > 10 kDa, corresponding to unhydrolysed proteins. However, in all 253 hydrolysates the largest proportion (70 > %) of material was < 5 kDa, showing that most intact 254 proteins were degraded during the hydrolytic reaction. This was also illustrated by the differences 255 in peptide profiles between the intact and hydrolysed MPI ( Fig. 2A) . In the hydrolysates (H4 and 256 H11), the peaks corresponding to intact proteins seen in the MPI RP-UPLC profile were only 257 present at low intensity. Hydrolysates contained numerous peptide peaks eluting throughout the 258 chromatogram. When comparing two hydrolysates (H4 and H11) having the same DPP-IV 259 inhibitory properties (Table 1) , minor differences in terms of occurrence and intensity of peptide 260 peaks were seen on the RP-profiles ( Fig. 2A) . The DH of the MPI hydrolysates generated withinthe DOE is reported is Similarly to the DH, no significant differences (p > 0.05, Table 1 The complete and simplified MLR models both gave a good fit of the experimental DPP-IV IC 50 285 values as indicated by the non-significant lack of fit (p > 0.05, Table 2 ). Two parameters of the 286 significant effect (p > 0.05). The significance of t 2 (p < 0.05), was linked with the existence of an 288 optimum time within the DOE boundaries. Both coefficients associated with E:S and t were 289 negative, indicating that an increase in E:S or t would result in a reduction in DPP-IV IC 50 value. 290
The complete model gave a better correlation between the experimental and predicted DPP-IV 291 IC 50 values ( Table 2 and Supplementary Fig. S1 ). Therefore, the complete model was employed 292 to build the RSM curves. The RSM curves showed a lower DPP-IV IC 50 value when either E:S or 293 t were at the +1 (2.00 % E:S and 240 min) vs the -1 (0.50 % and 60 min) level (Fig. 3A, 3B and 294 3C). In contrast, the temperature value minimally affected the DPP-IV IC 50 value ( observed in this study. The lack of a temperature effect may arise from the fact that the 300 temperature range studied was within the optimum range for this trypsin preparation. 301
Physicochemical characteristics and DPP-IV inhibitory properties of the MPI 302 hydrolysate (H16) predicted by RSM to yield low DPP-IV IC 50 values 303
Hydrolysis conditions predicted to yield DPP-IV IC 50 values < 0.7 mg mL -1 (low DPP-IV IC 50 304 value range Supplementary Fig S2) were selected within the boundaries of the DOE as 50.5C (T 305 = +0.05), 231 min (t = +0.90) and 2% E:S (+1.00). These conditions were used to externally 306 validate the predictive model. The complete and simplified models predicted that this hydrolysate 307 (H16) would yield a DPP-IV IC 50 value of 0.69 and 0.68 mg mL -1 , respectively. 308
The corresponding hydrolysates (H16A, H16B and H16C) had a similar DH (mean value of 309 12.96  1.51%, p > 0.05, Table 1 ). All three hydrolysates, which contained > 90% material < 5 310 kDa, displayed similar molecular mass distribution profiles (Fig. 1) . The DPP-IV IC 50 values ofdetermined (mean value of 0.66  0.10 mg mL -1 ) and predicted (0.69/0.68 mg mL -1 ) DPP-IV Supplementary Fig. S2A and S2B) . Furthermore, inhibition of trypsin by 320 peptides released during hydrolytic reactions may also occur (Iametti et al., 2002) . 321
DPP-IV inhibitory properties of H16B and MPI following SGID 322
Hydrolysate H16B was subjected to the SGID protocol. Hydrolysates H16B before and after 323 pepsin digestion (H16B_pepsin) had similar molecular mass distribution (Fig. 1) as well as 324 peptide profiles (Fig. 2B) . The pepsin and CorPP digest (H16B_CorPP) had a different molecular 325 mass distribution (Fig. 1) from H16B , showing > 99% of the material present within 326 H16B_CorPP being < 5 kDa vs. ~ 94% in H16B. Differences were also seen in the RP-UPLC 327 peptide profiles of H16B and H16B_CorPP (Fig. 2B) , notably in terms of peptide peaks eluting 328 before 10 and after 15 min. Following SGID of MPI, major differences were seen in the 329 molecular mass distribution, indicating significant protein breakdown in the MPI both after 330 pepsin (MPI_pepsin) and CorPP (MPI_CorPP) digestion (Fig. 1) . The MPI proteins were also 331 degraded in MPI_pepsin and MPI_CorPP as indicated by the RP-profiles (Fig. 2C) . 332 A significant increase in the DPP-IV IC 50 value of H16B (0.62  0.11 mg mL -1 ) was seen in 333
H16B_pepsin and H16B_CorPP (0.87  0.05 and 0.90  0.07 mg mL -1 , respectively, p < 0.05, 334 6.0S, the commercial trypsin preparation used during the generation of H16B, and CorPP. In fact 353 certain peptides released by PTN 6.0S were not further degraded following SGID (Table 3) . 354
Peptide identification within MPI hydrolysates 355
Various MPI hydrolysates (e.g., H4, H11 and H16B) displayed the same DPP-IV IC 50 value (p > 356 0.05, Table 1 ). Despite similarities in their DPP-IV inhibitory potency, some differences in the 357 presence of known DPP-IV inhibitory peptides within these hydrolysates were seen (Table 3) . 358
Numerous DPP-IV inhibitory peptides were common between the three samples, some of which 359 were relatively potent, having IC 50 values < 100 µM. The most potent peptide identified within 360 these samples was Ile-Asn-Asn-Gln-Phe-Leu-Pro-Tyr-Pro-Tyr (κ-CN (f51-60)), which had aidentified DPP-IV inhibitory peptides present within H4 were also observed within H11 and 363 H16B. In addition to these 18 DPP-IV inhibitory peptides identified in H4, H16B also contained 364 a particularly potent DPP-IV inhibitor, Val-Pro-Leu ( s1 -CN (f167-169)), known as Diprotin B, 365 having a DPP-IV IC 50 value of 15.8 µM (Umezawa et al., 1984) , which was not found within H4 366 or H11. In agreement with trypsin and chymotrypsin specificity, numerous peptides possessing 367
Arg, Lys, Tyr, Trp and Phe residues at their C-terminus were identified within H4, H11 and 368 H16B (Table 3 and 4) . 369
In addition to known DPP-IV inhibitory peptides, the hydrolysates contained peptides possessing 370 the features of DPP-IV inhibitory peptides (i.e., Leu, Ile or Phe at the N-terminus and/or Pro/Ala 371 at position 2, and/or Pro at the C-terminus). The peptides with the above features identified 372 within H16B are summarised in Table 4 . H16B did not contain peptides with a Trp at the N-373 terminus. However, peptides possessing one or several of the other features were identified. 374
While the DPP-IV inhibitory potential of the majority of the peptides reported in Table 4 is 375 unknown, they may play a role in the overall DPP-IV inhibitory activity of H16B. In particular, 376 peptides (possessing a Pro or Ala at the penultimate position) which can act as substrates for 377 DPP-IV are likely to interact with its active site and induce a substrate-type inhibition effect 378 (Nongonierma & FitzGerald, 2014b). Interestingly, a number of substrate-like peptides, mostly 379 arising from CNs, were identified within H16B (Table 4) . Leu/Ile residues at the N-terminus of 380 peptides within H16B were also frequently found, arising from either CNs or whey proteins 381 (Table 4) All previously identified DPP-IV inhibitory peptides within H16B were also found within 386 H16B_CorPP (Table 3) , with the exception of Ile-Pro-Ala-Val-Phe (-Lg (f78-82)), Ile-Pro-Ala-387
Val-Phe-Lys (-Lg (f78-83)) and Val-Ala-Gly-Thr-Trp-Tyr (-Lg (f15-20)). H16B_CorPPcontained one previously identified DPP-IV inhibitory peptide, Leu-Lys-Pro-Thr-Pro-Glu-Gly-389
Asp-Leu (-Lg (f46-54)), which was not found within H16B. Following SGID of H16B, some of 390 the known DPP-IV inhibitory peptides (i.e., Ile-Pro-Ala-Val-Phe and Ile-Pro-Ala-Val-Phe-Lys) 391 appeared to have been degraded by the hydrolytic activity of enzymes present within pepsin or 392
CorPP preparations. The decrease of DPP-IV inhibitory activity of H16B_CorPP compared to 393 H16B ( Table 1 ) may indicate that these peptides play an important role in the overall bioactivity 394 of H16B. 395
All 17 of the previously identified DPP-IV inhibitory peptides within MPI_CorPP were the same 396 as those found within H16B_CorPP (Table 3 ). This may partly explain why both samples had the 397 same DPP-IV inhibitory potency (Table 1 ). The benefit of prehydrolysing MPI with PTN 6.0S 398 could not be demonstrated as H16B_CorPP and MPI_CorPP had the same DPP-IV IC 50 value 399 (Table 1) . In vivo evaluation of MPI and H16 is required to demonstrate the significance of the 400 results reported herein to the potential in vivo DPP-IV inhibitory activity of these hydrolysates. 
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